Sonia Dolfi

1.6k total citations
33 papers, 756 citations indexed

About

Sonia Dolfi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Sonia Dolfi has authored 33 papers receiving a total of 756 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 17 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Sonia Dolfi's work include Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (14 papers) and Melanoma and MAPK Pathways (8 papers). Sonia Dolfi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), CAR-T cell therapy research (14 papers) and Melanoma and MAPK Pathways (8 papers). Sonia Dolfi collaborates with scholars based in United States, Italy and Australia. Sonia Dolfi's co-authors include Kim M. Hirshfield, Alexei Vázquez, Zoltán N. Oltvai, Joseph R. Bertino, Philip M. Tedeschi, Leo Li‐Ying Chan, Jean Qiu, Robert S. DiPaola, Murugesan Gounder and Shridar Ganesan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sonia Dolfi

32 papers receiving 743 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sonia Dolfi United States	14	431	289	223	115	56	33	756
Sangeetha Palakurthi United States	11	654 1.5×	278 1.0×	237 1.1×	162 1.4×	49 0.9×	22	931
Nobuhiro Tanuma Japan	18	787 1.8×	246 0.9×	304 1.4×	167 1.5×	50 0.9×	41	1.0k
Jay Mei United States	13	451 1.0×	236 0.8×	139 0.6×	66 0.6×	33 0.6×	47	808
Kim R. Kampen Netherlands	21	910 2.1×	215 0.7×	285 1.3×	119 1.0×	69 1.2×	47	1.3k
Karolina Sterzyńska Poland	18	428 1.0×	325 1.1×	226 1.0×	101 0.9×	67 1.2×	36	811
Jangsoon Lee United States	18	684 1.6×	434 1.5×	166 0.7×	84 0.7×	90 1.6×	40	1.1k
Jiazheng Sun China	13	315 0.7×	176 0.6×	191 0.9×	60 0.5×	73 1.3×	20	606
Mousumi Majumder Canada	15	478 1.1×	346 1.2×	288 1.3×	137 1.2×	56 1.0×	21	903
Miljan Kuljanin United States	15	781 1.8×	257 0.9×	135 0.6×	63 0.5×	49 0.9×	30	1.1k
Shikha Gaur United States	16	487 1.1×	218 0.8×	206 0.9×	87 0.8×	87 1.6×	28	875

Countries citing papers authored by Sonia Dolfi

Since Specialization

Citations

This map shows the geographic impact of Sonia Dolfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonia Dolfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonia Dolfi more than expected).

Fields of papers citing papers by Sonia Dolfi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonia Dolfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonia Dolfi. The network helps show where Sonia Dolfi may publish in the future.

Co-authorship network of co-authors of Sonia Dolfi

This figure shows the co-authorship network connecting the top 25 collaborators of Sonia Dolfi. A scholar is included among the top collaborators of Sonia Dolfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonia Dolfi. Sonia Dolfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lipson, Evan J., F. Stephen Hodi, Hussein Tawbi, et al.. (2025). Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. European Journal of Cancer. 225. 115547–115547. 1 indexed citations

Ascierto, Paolo A., Sonia Dolfi, Marta Nyakas, et al.. (2025). Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. Journal for ImmunoTherapy of Cancer. 13(2). e009773–e009773. 1 indexed citations

Long, Georgina V., Paolo A. Ascierto, Jun Guo, et al.. (2025). Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.. Journal of Clinical Oncology. 43(17_suppl). 2 indexed citations

Ferguson, Robert, Sonia Dolfi, Daniel J. Tenney, et al.. (2024). Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy–Induced Immune-Related Adverse Events in Melanoma. Clinical Cancer Research. 30(19). 4412–4423. 2 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2024). Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. Journal of Clinical Oncology. 43(13). 1546–1552. 24 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2024). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.. Journal of Clinical Oncology. 42(16_suppl). 9524–9524. 7 indexed citations

Schadendorf, Dirk, Hussein A. Tawbi, F. Stephen Hodi, et al.. (2024). 1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047. Annals of Oncology. 35. S723–S724. 1 indexed citations

Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2023). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.. Journal of Clinical Oncology. 41(16_suppl). 9502–9502. 7 indexed citations

10.

Wiggins, Jennifer, Hao Tang, Keyur Desai, et al.. (2023). Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.. Journal of Clinical Oncology. 41(16_suppl). 9577–9577. 3 indexed citations

11.

Lipson, Evan J., Sonia Dolfi, Hao Tang, et al.. (2023). LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047. Annals of Oncology. 34. S1290–S1291. 3 indexed citations

12.

Garman, Bradley, Can Jiang, Sherif Daouti, et al.. (2023). Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. Frontiers in Immunology. 14. 1151748–1151748. 9 indexed citations

13.

Long, Georgina V., F. Stephen Hodi, Dirk Schadendorf, et al.. (2023). 1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047. Annals of Oncology. 34. S664–S665. 4 indexed citations

14.

Long, Georgina V., Keyur Desai, Tania Tang, et al.. (2022). 788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). Annals of Oncology. 33. S904–S904. 14 indexed citations

15.

Teh, Jessica L.F., Sonia Dolfi, Sameera Kongara, et al.. (2015). Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. Breast Cancer Research and Treatment. 151(1). 57–73. 28 indexed citations

16.

Dolfi, Sonia, et al.. (2014). Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer Letters. 350(1-2). 52–60. 26 indexed citations

17.

Dolfi, Sonia, et al.. (2014). Abstract 4457: Regulation of GRM1 by estrogen receptor in breast cancer. Cancer Research. 74(19_Supplement). 4457–4457. 2 indexed citations

18.

Dolfi, Sonia, Leo Li‐Ying Chan, Jean Qiu, et al.. (2013). The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & Metabolism. 1(1). 20–20. 147 indexed citations

19.

Tedeschi, Philip M., Elke Markert, Murugesan Gounder, et al.. (2013). Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death and Disease. 4(10). e877–e877. 207 indexed citations

20.

Lin, Siang-Yo, Sonia Dolfi, Sohrab Amiri, et al.. (2013). P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms. International Journal of Oncology. 43(6). 1817–1823. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact